Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 2/20 | 0.74 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.64 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.64 |
| ▸ | NT5E | P21589 | 2/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.61 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.52 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15794401 | 0.93 | P2RX3 (0.76) | DNPH1P2RX3P2RX2NT5ESLC29A1 | |
| SCHEMBL14873506 | 0.93 | P2RX3 (0.76) | DNPH1P2RX3P2RX2NT5ESLC29A1 | |
| SCHEMBL19699214 | 0.92 | DNPH1 (0.63) | DNPH1P2RX3P2RX2NT5ESLC29A1 | |
| SCHEMBL19699228 | 0.92 | DNPH1 (0.63) | DNPH1P2RX3P2RX2NT5ESLC29A1 | |
| SCHEMBL19699276 | 0.91 | DNPH1 (0.62) | DNPH1P2RX3P2RX2NT5ESLC29A1 | |
| SCHEMBL19699281 | 0.88 | DNPH1 (0.59) | DNPH1P2RX3P2RX2NT5ESLC29A1 | |
| SCHEMBL19699255 | 0.87 | DNPH1 (0.57) | DNPH1P2RX3P2RX2NT5ESLC29A1 | |
| SCHEMBL17875220 | 0.87 | SLC29A1 (0.60) | DNPH1P2RX3P2RX2NT5ESLC29A1 | |
| SCHEMBL1796246 | 0.87 | SLC29A1 (0.60) | DNPH1P2RX3P2RX2NT5ESLC29A1 | |
| SCHEMBL10186161 | 0.87 | SLC29A1 (0.60) | DNPH1P2RX3P2RX2NT5ESLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | DNPH1 2051/4885P2RX3 884/4885P2RX2 1459/4885 |
| US-20170354673-A1 | OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF | RNGTT, UPF1, NSUN3 | DNPH1 2035/4885P2RX3 925/4885P2RX2 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.